Home > Insider Trading > Filing (0000914190-21-000185)

Filing Details

Accession Number:: 0000914190-21-000185
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-06-16 19:22:16
Reporting Period:: 2021-06-14

Accepted Time:: 2021-06-16 19:22:16
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
842023	Bio-Techne Corp	TECH	Biological Products, (No Disgnostic Substances) (2836)	411427402

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1534980	R. Charles Kummeth	614 Mckinley Place Ne Minneapolis MN 55413	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-06-14	7,132	$449.10	167,253	No	4	S	Direct
Common Stock	Disposition	2021-06-14	349	$450.10	166,904	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	100	Indirect	By Step-Son
Common Stock	100	Indirect	By Step-Daughter

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Options (Right to Buy)	$108.49	2022-08-07	95,346	95,346	Direct
Common Stock	Stock Options (Right to Buy)	$108.49	2022-08-07	79,517	79,517	Direct
Common Stock	Stock Options (Right to Buy)	$106.59	2023-08-18	154,169	154,169	Direct
Common Stock	Stock Options (Right to Buy)	$106.59	2023-08-18	102,779	102,779	Direct
Common Stock	Stock Options (Right to Buy)	$125.05	2024-08-09	117,342	117,342	Direct
Common Stock	Stock Options (Right to Buy)	$125.05	2024-08-09	78,228	78,228	Direct
Common Stock	Restricted Stock Units	$0.00		16,918	16,918	Direct
Common Stock	Stock Options (Right to Buy)	$177.32	2025-08-08	90,334	90,334	Direct
Common Stock	Stock Options (Right to Buy)	$177.32	2025-08-08	60,222	60,222	Direct
Common Stock	Restricted Stock Units	$0.00		16,937	16,937	Direct
Common Stock	Stock Options (Right to Buy)	$190.41	2026-08-07	85,725	85,725	Direct
Common Stock	Stock Options (Right to Buy)	$190.41	2026-08-07	57,150	57,150	Direct
Common Stock	Restricted Stock Units	$0.00		12,879	12,879	Direct
Common Stock	Stock Options (Right to Buy)	$267.87	2027-08-05	57,442	57,442	Direct
Common Stock	Stock Options (Right to Buy)	$267.87	2027-08-05	38,295	38,295	Direct
Common Stock	Stock Options (Right to Buy)	$267.87	2027-08-05	16,650	16,650	Direct
Common Stock	Stock Options (Right to Buy)	$267.87	2027-08-05	16,650	16,650	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2022-08-07	95,346	95,346	Direct
2022-08-07	79,517	79,517	Direct
2023-08-18	154,169	154,169	Direct
2023-08-18	102,779	102,779	Direct
2024-08-09	117,342	117,342	Direct
2024-08-09	78,228	78,228	Direct
	16,918	16,918	Direct
2025-08-08	90,334	90,334	Direct
2025-08-08	60,222	60,222	Direct
	16,937	16,937	Direct
2026-08-07	85,725	85,725	Direct
2026-08-07	57,150	57,150	Direct
	12,879	12,879	Direct
2027-08-05	57,442	57,442	Direct
2027-08-05	38,295	38,295	Direct
2027-08-05	16,650	16,650	Direct
2027-08-05	16,650	16,650	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $449.00 to $449.97, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023.
Fully exercisable.
Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
Options to purchase 19,557 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and 8/9/2021.
Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Options to purchase 15,056 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 15,055 shares vest on each of 8/8/2021 and 8/8/2022.
Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Options to purchase 14,288 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 14,287 shares vest on each of 8/7/2022 and 8/7/2023.
Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Options to purchase 9,573 shares vest on 8/5/21 and options to purchase 9,574 shares vest on each of 8/5/22, 8/5/23 and 8/5/24.
Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
Options to purchase 5,550 shares vest on each of 8/5/21, 8/5/22 and 8/5/23.